

# BAM7

**Catalog No: tcsc1453**



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

331244-89-4

**Formula:**

$C_{21}H_{19}N_5O_2S$

**Pathway:**

Apoptosis

**Target:**

Bcl-2 Family

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 5 mg/mL (12.33 mM; Need ultrasonic)

**Observed Molecular Weight:**

405.47


## Product Description

BAM7 is a direct and selective activator of proapoptotic **BAX** with an **IC<sub>50</sub>** of 3.3 μM.

IC50 & Target: IC50: 3.3 μM (BAX)<sup>[1]</sup>

**In Vitro:** BAM7 is selective for the BH3-binding site on BAX. BAM7 activates BAX and BAX-dependent cell death. Whereas treatment with BAX or BAM7 alone has no effect on the liposomes, the combination of BAM7 and BAX yields dose-responsive liposomal release

of entrapped fluorophore. BAM7 dose- and time-responsively impairs the viability of *Bak*<sup>-/-</sup> MEFs that exclusively express BAX but has no effect on *Bak*<sup>-/-</sup> MEFs that contain BAK but lack BAX. In contrast, standard proapoptotic stimuli such as serum withdrawal, Staurosporine and Etoposide induces an equivalent apoptotic response in *Bax*<sup>-/-</sup> and *Bak*<sup>-/-</sup> MEFs. As further evidence of BAM7 specificity of action, (i) BAM7 does not affect the viability of *Bax*<sup>-/-</sup> *Bak*<sup>-/-</sup> MEFs; (ii) ANA-BAM16, which does not bind or activate BAX, has no effect on *Bak*<sup>-/-</sup> MEFs; and (iii) BAM7 selectively induces cell death of *Bax*<sup>-/-</sup> *Bak*<sup>-/-</sup> MEFs reconstituted with wild-type BAX but not BAXK21E, which bears the mutation that abrogates BAM7 binding<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!